Aldeyra Therapeutics, Inc.
ALDX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $48 | $29 | $47 | $45 |
| G&A Expenses | $12 | $13 | $15 | $11 |
| SG&A Expenses | $12 | $13 | $15 | $11 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $60 | $43 | $63 | $56 |
| Operating Income | -$60 | -$43 | -$63 | -$56 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $4 | $5 | $1 | -$2 |
| Pre-Tax Income | -$56 | -$38 | -$62 | -$58 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$56 | -$38 | -$62 | -$58 |
| % Margin | – | – | – | – |
| EPS | -0.94 | -0.64 | -1.06 | -1.07 |
| % Growth | -46.9% | 39.6% | 0.9% | – |
| EPS Diluted | -0.94 | -0.64 | -1.06 | -1.07 |
| Weighted Avg Shares Out | 59 | 59 | 58 | 54 |
| Weighted Avg Shares Out Dil | 59 | 59 | 58 | 54 |
| Supplemental Information | – | – | – | – |
| Interest Income | $6 | $7 | $2 | $0 |
| Interest Expense | $2 | $2 | $2 | $2 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$54 | -$35 | -$60 | -$56 |
| % Margin | – | – | – | – |